CoChat

The Epigenetic Evolution of Glioma Is Determined by the IDH1 Mutation Status and Treatment Regimen

Open access
Malta, Tathiane M., Sabedot, Thais S., Morosini, Natalia S., Datta, Indrani, Garofano, Luciano, Vallentgoed, Wies, Varn, Frederick S., Aldape, Kenneth, D'Angelo, Fulvio, Bakas, Spyridon, Barnholtz-Sloan, Jill S., Gan, Hui K., Hasanain, Mohammad, Hau, Ann-Christin, Johnson, Kevin C., Cazacu, Simona, deCarvalho, Ana C., Khasraw, Mustafa, Kocakavuk, Emre, Kouwenhoven, Mathilde C.M., Migliozzi, Simona, Niclou, Simone P., Niers, Johanna M., Ormond, D. Ryan, Paek, Sun Ha, Reifenberger, Guido, Sillevis Smitt, Peter A., Smits, Marion, Stead, Lucy F., van den Bent, Martin J., Van Meir, Erwin G., Walenkamp, Annemiek, Weiss, Tobias, Weller, Michael, Westerman, Bart A., Ylstra, Bauke, Wesseling, Pieter, Lasorella, Anna, French, Pim J., Poisson, Laila M., Consortium The GLASS, Woehrer, Adelheid, Lowman, Allison K, deCarvalho, Ana C, Castro, Ana Valeria, Transou, Andrea, Brodbelt, Andrew R, Hau, Ann-Christin, Lasorella, Anna, Golebiewska, Anna, Walenkamp, Annemiek, Molinaro, Annette M, Iavarone, Antonio, Ismail, Azzam, Westerman, Bart A, Ylstra, Bauke, Bock, Christoph, Ormond, D. Ryan, Brat, Daniel J, Kocakavuk, Emre, Van Meir, Erwin G, Barthel, Floris P, Varn, Frederick S, D'Angelo, Fulvio, Finocchiaro, Gaetano, Rao, Ganesh, Zadeh, Gelareh, Reifenberger, Guido, ngNg, Ho Keu, Kim, Hoon, Noushmehr, Houtan, Miletic, Hrvoje, Gan, Hui K, Datta, Indrani, Rock, Jack, Snyder, James M, Huse, Jason T, Connelly, Jennifer M, Barnholtz-Sloan, Jill S, Niers, Johanna M, deGroot, John F, Akdemir, Kadir C, Kannan, Kasthuri S, Ligon, Keith L, Aldape, Kenneth, Bulsara, Ketan R, Johnson, Kevin C, Alfaro, Kristin D, Poisson, Laila M, Garofano, Luciano, Stead, Lucy F, Nasrallah, MacLean P, Smits, Marion, van den Bent, Martin J, Kouwenhoven, Mathilde CM, Weller, Michael, Hasanain, Mohammad, Khasraw, Mustafa, Gould, Peter V, Smitt, Peter A Sillevis, LaViolette, Peter S, Tatman, Philip D, Wesseling, Pieter, French, Pim J, Beroukhim, Rameen, Verhaak, Roel G.W., Migliozzi, Simona, Niclou, Simone P, Bakas, Spyridon, Kalkanis, Steven, Paek, Sun Ha, Short, Susan C, Ghazaleh, Tabatabai, Malta, Tathiane M, Sabedot, Thais S, Weiss, Tobias, Walbert, Tobias, Baid, Ujjwal, Vallentgoed, Wies, Yung, W. K. Alfred, Verhaak, Roel G.W., Iavarone, Antonio, Noushmehr, Houtan · 2024 · Cancer Research

Published version of a preprint

The DOI matches its Crossref record; 98 of the 98 references it cites were found in a registry or an index.

Abstract

Tumor adaptation or selection is thought to underlie therapy resistance in glioma. To investigate longitudinal epigenetic evolution of gliomas in response to therapeutic pressure, we performed an epigenomic analysis of 132 matched initial and recurrent tumors from patients with IDH-wildtype (IDHwt) and IDH-mutant (IDHmut) glioma. IDHwt gliomas showed a stable epigenome over time with relatively low levels of global methylation. The epigenome of IDHmut gliomas showed initial high levels of genome-wide DNA methylation that was progressively reduced to levels similar to those of IDHwt tumors. Integration of epigenomics, gene expression, and functional genomics identified HOXD13 as a master regulator of IDHmut astrocytoma evolution. Furthermore, relapse of IDHmut tumors was accompanied by histologic progression that was associated with survival, as validated in an independent cohort. Finally, the initial cell composition of the tumor microenvironment varied between IDHwt and IDHmut tumors and changed differentially following treatment, suggesting increased neoangiogenesis and T-cell infiltration upon treatment of IDHmut gliomas. This study provides one of the largest cohorts of paired longitudinal glioma samples with epigenomic, transcriptomic, and genomic profiling and suggests that treatment of IDHmut glioma is associated with epigenomic evolution toward an IDHwt-like phenotype. Significance: Standard treatments are related to loss of DNA methylation in IDHmut glioma, resulting in epigenetic activation of genes associated with tumor progression and alterations in the microenvironment that resemble treatment-naïve IDHwt glioma.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-23-2093

Cites

98 of 98 references verified0 citation errors · 0 not checkable

Statistics

Figures

Graphical abstract
Graphical abstract CC BY-NC-ND · PubMed Central
Figure 1. Epigenomic evolution of matched initial and recurrent gliomas. A, Venn diagram of number of patients who had DNA methylation, genomic (WGS/WXS), and/or RNA sequencing profiling. B, Clinical and molecular overview of matched initial and first recurrent DNA methylation cohort. Each column represents a single patient (N = 132) at two separate time points grouped by IDH status and ordered by increase of gain of DNA methylation at recurrent tumor from left to right. The gain of DNA methylation represents the percentage of probes that showed an increase of DNA methylation at recurrence. Top plot shows the surgical interval of each patient. C, Frequency of patients with hypermutator tumors that switched or retained molecular subtype at recurrence. Patients are distinguished by IDH status.
Figure 1. Epigenomic evolution of matched initial and recurrent gliomas. A, Venn diagram of number of patients who had DNA methylation, genomic (WGS/WXS), and/or RNA sequencing profiling. B, Clinical and molecular overview of matched initial and first recurrent DNA methylation cohort. Each column represents a single patient (N = 132) at two separate time points grouped by IDH status and ordered by increase of gain of DNA methylation at recurrent tumor from left to right. The gain of DNA methylation represents the percentage of probes that showed an increase of DNA methylation at recurrence. Top plot shows the surgical interval of each patient. C, Frequency of patients with hypermutator tumors that switched or retained molecular subtype at recurrence. Patients are distinguished by IDH status.CC BY-NC-ND · PubMed Central
Figure 2. Master regulators associated with IDHmut glioma recurrence/progression. A, Starburst plot of all H3K27ac and H3K4me3 peaks overlapping known transcription start sites. Significant gains or losses of H3K27ac (y-axis) and H3K4me3 (x-axis) are highlighted. Each dot indicates a gene and the shape indicates the expression difference between GCIMP-low versus GCIMP-high. Triangles, upregulated genes; squares, downregulated genes. If a gene is enriched for both H3K27ac and H3K4me3, this implies active TSS and the associated gene expression is defined as upregulated (turquoise, top right corner). If a gene is depleted for both H3K4me3 and H3K27ac, this implies weak or quiescent expression of the associated gene (green, bottom left corner). Gray, not significant gene promoter enrichment. Only the most significant upregulated genes are labeled in this plot. B, Genome browser representation focused on the HOXD family. The region related to HOXD13 gene (hg18.chr2: 176,092,721–176,095,944) is highlighted in turquoise. HOXD13 is more enriched by the H3K27ac and H3K4me3 peaks in the GCIMP-Low (recurrent) samples (n = 3) than in their corresponding GCIMP-High (primary) pairs (n = 3), top and bottom graph, respectively. C, HOXD13 expression level by RNA sequencing of GLASS IDHmut samples stratified by initial/recurrent and codel status (N = 11 codels and 26 noncodels patients). Each box represents quartiles, and the center line represents the median of each group. The whiskers represent absolute range. D, Stemness activity in the GLASS IDHmut samples stratified by initial/recurrent and codel status. Each box represents quartiles, and the center line represents the median of each group. The whiskers represent absolute range. E, Quantification analysis of the relative HOXD13 expression levels (2-ΔΔCt) between samples: control, n = 2; HOXD13 1 sgRNA HOXD13–07, n = 2; HOXD13 2 sgRNA HOXD13–55, n = 2 biological replicates. The boxplots represent the analysis of three technical replicates for each sample. F, Proliferation growth curve over 9 days of analysis (control, N = 2; HOXD13 1 sgRNA HOXD13–07, N = 2; HOXD13 2 sgRNA HOXD13–55, N = 2 biological replicates). **, P < 0.01
Figure 2. Master regulators associated with IDHmut glioma recurrence/progression. A, Starburst plot of all H3K27ac and H3K4me3 peaks overlapping known transcription start sites. Significant gains or losses of H3K27ac (y-axis) and H3K4me3 (x-axis) are highlighted. Each dot indicates a gene and the shape indicates the expression difference between GCIMP-low versus GCIMP-high. Triangles, upregulated genes; squares, downregulated genes. If a gene is enriched for both H3K27ac and H3K4me3, this implies active TSS and the associated gene expression is defined as upregulated (turquoise, top right corner). If a gene is depleted for both H3K4me3 and H3K27ac, this implies weak or quiescent expression of the associated gene (green, bottom left corner). Gray, not significant gene promoter enrichment. Only the most significant upregulated genes are labeled in this plot. B, Genome browser representation focused on the HOXD family. The region related to HOXD13 gene (hg18.chr2: 176,092,721–176,095,944) is highlighted in turquoise. HOXD13 is more enriched by the H3K27ac and H3K4me3 peaks in the GCIMP-Low (recurrent) samples (n = 3) than in their corresponding GCIMP-High (primary) pairs (n = 3), top and bottom graph, respectively. C, HOXD13 expression level by RNA sequencing of GLASS IDHmut samples stratified by initial/recurrent and codel status (N = 11 codels and 26 noncodels patients). Each box represents quartiles, and the center line represents the median of each group. The whiskers represent absolute range. D, Stemness activity in the GLASS IDHmut samples stratified by initial/recurrent and codel status. Each box represents quartiles, and the center line represents the median of each group. The whiskers represent absolute range. E, Quantification analysis of the relative HOXD13 expression levels (2-ΔΔCt) between samples: control, n = 2; HOXD13 1 sgRNA HOXD13–07, n = 2; HOXD13 2 sgRNA HOXD13–55, n = 2 biological replicates. The boxplots represent the analysis of three technical replicates for each sample. F, Proliferation growth curve over 9 days of analysis (control, N = 2; HOXD13 1 sgRNA HOXD13–07, N = 2; HOXD13 2 sgRNA HOXD13–55, N = 2 biological replicates). **, P < 0.01CC BY-NC-ND · PubMed Central
Figure 3. DNA methylation loss associates with malignant transformation of glioma after standard treatment. A, Heat map of DNA methylation data. Hierarchical clustering analysis of 620 CpG probes that are associated with different treatment strategies in IDHmut paired glioma samples. Columns represent glioma samples; rows represent CpG probes. Samples were stratified and clustered on the basis of IDH mutation status and initial/recurrent status and CpGs were ordered using hierarchical clustering methods. Nonneoplastic brain samples are represented on the left of the heat map. DNA methylation β values range from 0 (low) to 1 (high). Additional tracks are included at the top of the heat maps to identify each sample membership within separate cluster analysis. B, Heat map of DNA methylation data in the validation cohort - GLASS-NL, showing the same 620 CpG probes of A. C, Boxplot of the average DNA methylation β value of the 620 CpG probes from A, in IDHmut samples. Samples are stratified by initial/recurrent status and by treated/nontreated status. Left, GLASS-International samples; right, GLASS-NL samples. Each box represents quartiles, and the center line represents the median of each group. The whiskers represent absolute range. D, Evolution of tumor histology (2021 WHO classification) from initial to recurrent samples after treatment compared with nontreated gliomas. E, Scatter plot of mean DNA methylation of CpG probes and mean gene expression of the epigenetically regulated genes after treatment (Supplementary Table S5). Each dot is a sample.
Figure 3. DNA methylation loss associates with malignant transformation of glioma after standard treatment. A, Heat map of DNA methylation data. Hierarchical clustering analysis of 620 CpG probes that are associated with different treatment strategies in IDHmut paired glioma samples. Columns represent glioma samples; rows represent CpG probes. Samples were stratified and clustered on the basis of IDH mutation status and initial/recurrent status and CpGs were ordered using hierarchical clustering methods. Nonneoplastic brain samples are represented on the left of the heat map. DNA methylation β values range from 0 (low) to 1 (high). Additional tracks are included at the top of the heat maps to identify each sample membership within separate cluster analysis. B, Heat map of DNA methylation data in the validation cohort - GLASS-NL, showing the same 620 CpG probes of A. C, Boxplot of the average DNA methylation β value of the 620 CpG probes from A, in IDHmut samples. Samples are stratified by initial/recurrent status and by treated/nontreated status. Left, GLASS-International samples; right, GLASS-NL samples. Each box represents quartiles, and the center line represents the median of each group. The whiskers represent absolute range. D, Evolution of tumor histology (2021 WHO classification) from initial to recurrent samples after treatment compared with nontreated gliomas. E, Scatter plot of mean DNA methylation of CpG probes and mean gene expression of the epigenetically regulated genes after treatment (Supplementary Table S5). Each dot is a sample.CC BY-NC-ND · PubMed Central
Figure 4. Tumor microenvironment and clinical implications of treatment in IDH-mutant gliomas. A, CD31 and CD8 proportions (range scaled from 0 to 100%) in samples originating from IDHmut matched initial and recurrent tumors in treated and nontreated patients. Each box in A and B represents quartiles, and the center line represents the median of each group. The whiskers represent absolute range. B, Illustrative immunohistochemical stainings for two marker proteins (CD31 and CD8) in an individual patient showing change of levels of tumor-infiltrating immune cells between initial (left) and recurrent (right) tumors. CD8 stainings are shown in two different magnifications. Boxplots represent the number of CD31- (top) and CD8-positive cells (bottom) counted per area for individual patients. C and D, Overall survival and surgical interval analysis of IDHmut gliomas for the GLASS International (C) and GLASS-NL (D) cohorts.
Figure 4. Tumor microenvironment and clinical implications of treatment in IDH-mutant gliomas. A, CD31 and CD8 proportions (range scaled from 0 to 100%) in samples originating from IDHmut matched initial and recurrent tumors in treated and nontreated patients. Each box in A and B represents quartiles, and the center line represents the median of each group. The whiskers represent absolute range. B, Illustrative immunohistochemical stainings for two marker proteins (CD31 and CD8) in an individual patient showing change of levels of tumor-infiltrating immune cells between initial (left) and recurrent (right) tumors. CD8 stainings are shown in two different magnifications. Boxplots represent the number of CD31- (top) and CD8-positive cells (bottom) counted per area for individual patients. C and D, Overall survival and surgical interval analysis of IDHmut gliomas for the GLASS International (C) and GLASS-NL (D) cohorts.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 98 references

Cited by

See all 68

Metadata

Authors
Malta, T. M., Sabedot, T. S., Morosini, N. S., Datta, I., Garofano, L., Vallentgoed, W., Varn, F. S., Aldape, K., D'Angelo, F., Bakas, S., Barnholtz-Sloan, J. S., Gan, H. K., Hasanain, M., Hau, A.-C., Johnson, K. C., Cazacu, S., deCarvalho, A. C., Khasraw, M., Kocakavuk, E., Kouwenhoven, M. C. M., Migliozzi, S., Niclou, S. P., Niers, J. M., Ormond, D. R., Paek, S. H., Reifenberger, G., Sillevis Smitt, P. A., Smits, M., Stead, L. F., van den Bent, M. J., Van Meir, E. G., Walenkamp, A., Weiss, T., Weller, M., Westerman, B. A., Ylstra, B., Wesseling, P., Lasorella, A., French, P. J., Poisson, L. M., Consortium The GLASS, Woehrer, A., Lowman, A. K., deCarvalho, A. C., Castro, A. V., Transou, A., Brodbelt, A. R., Hau, A.-C., Lasorella, A., Golebiewska, A., Walenkamp, A., Molinaro, A. M., Iavarone, A., Ismail, A., Westerman, B. A., Ylstra, B., Bock, C., Ormond, D. R., Brat, D. J., Kocakavuk, E., Van Meir, E. G., Barthel, F. P., Varn, F. S., D'Angelo, F., Finocchiaro, G., Rao, G., Zadeh, G., Reifenberger, G., ngNg, H. K., Kim, H., Noushmehr, H., Miletic, H., Gan, H. K., Datta, I., Rock, J., Snyder, J. M., Huse, J. T., Connelly, J. M., Barnholtz-Sloan, J. S., Niers, J. M., deGroot, J. F., Akdemir, K. C., Kannan, K. S., Ligon, K. L., Aldape, K., Bulsara, K. R., Johnson, K. C., Alfaro, K. D., Poisson, L. M., Garofano, L., Stead, L. F., Nasrallah, M. P., Smits, M., van den Bent, M. J., Kouwenhoven, M. C., Weller, M., Hasanain, M., Khasraw, M., Gould, P. V., Smitt, P. A. S., LaViolette, P. S., Tatman, P. D., Wesseling, P., French, P. J., Beroukhim, R., Verhaak, R. G. W., Migliozzi, S., Niclou, S. P., Bakas, S., Kalkanis, S., Paek, S. H., Short, S. C., Ghazaleh, T., Malta, T. M., Sabedot, T. S., Weiss, T., Walbert, T., Baid, U., Vallentgoed, W., Yung, W. K. A., Verhaak, R. G. W., Iavarone, A., & Noushmehr, H.
Affiliations
  • Henry Ford Health (US)
  • 16Department of Neurology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.
  • Yale University (US)
Venue
Cancer Research
Published
2023-12-20
Volume
84
Issue
5
Pages
741-756
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W4389992531
Cited by
68
References
97
Citations by year
2026: 23 · 2025: 24 · 2024: 19
FWCI
11.39
Type
journal article
Language
en
Open access
Locations
  • Cancer Research (publishedVersion, cc-by-nc-nd)
  • bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion, other-oa)
  • EUR Research Repository (Erasmus University Rotterdam) (publishedVersion, cc-by-nc-nd)
  • University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion, cc-by-nc-nd)
  • Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, cc-by-nc-nd)
  • White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (submittedVersion)
  • Open Repository and Bibliography (University of Luxembourg) (submittedVersion, cc-by-nc-nd)
  • Digital Commons-TMC (Texas Medical Center) (submittedVersion)
  • Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
  • The Mouseion at the JAXlibrary (Jackson Laboratory) (submittedVersion, cc-by-nc-nd)
  • Zurich Open Repository and Archive (University of Zurich) (submittedVersion, cc-by-nc-nd)
  • Zurich Open Repository and Archive (University of Zurich)
Funders
  • Fundação de Amparo à Pesquisa do Estado de São Paulo (2018/00583-0, 2019/14928-1)
  • National Institutes of Health (R01CA222146, R21 NS114873, Cancer Center Support Grant P30 CA034196, R01CA270365, R01NS096236, R01NS117666, R01NS042645, P50CA190991-07)
  • Fonds National de la Recherche Luxembourg (CORE C20/BM/14646004, FNRS-Televie TETHER)
  • Jackson Laboratory (JAX Scholar Program and a postdoctoral fellowship from The Jane Coffin Childs Memorial Fund for Medi)
  • U.S. Department of Defense (CA170278)
  • Anschutz Medical Campus, University of Colorado
Topics
  • Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
  • Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
Keywords
glioma, IDH mutation, epigenetic evolution, DNA methylation, treatment resistance, recurrent glioma, HOXD13, astrocytoma, tumor microenvironment, neoangiogenesis, T cell infiltration, tumor recurrence, histological progression, epigenetic reprogramming
MeSH terms
Brain Neoplasms, Glioma, Humans, Isocitrate Dehydrogenase, Mutation, Neoplasm Recurrence, Local, Epigenesis, Genetic, Epigenomics, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Epigenetic Evolution of Glioma Is Determined by the IDH1 Mutation Status and Treatment Regimen. https://app.cochat.ai/papers/10.1158/0008-5472.can-23-2093
The paper
Malta, T. M., Sabedot, T. S., Morosini, N. S., Datta, I., Garofano, L., Vallentgoed, W., Varn, F. S., Aldape, K., D'Angelo, F., Bakas, S., Barnholtz-Sloan, J. S., Gan, H. K., Hasanain, M., Hau, A.-C., Johnson, K. C., Cazacu, S., deCarvalho, A. C., Khasraw, M., Kocakavuk, E., . . . Noushmehr, H. (2024). The Epigenetic Evolution of Glioma Is Determined by the IDH1 Mutation Status and Treatment Regimen. Cancer Research. https://doi.org/10.1158/0008-5472.can-23-2093

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.